Sean Wharton

24PUBLICATIONS
62CO-AUTHORS
Isotope geochemistryPharmacogenomicsPharmaceutical delivery technologiesMetabolic medicineExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 24, 2026
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

|Jun 13, 2026
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.

|Apr 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.

|Nov 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Sean Wharton, Carel W le Roux, Biykem Bozkurt

|Nov 04, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Carel W le Roux, Sean Wharton, Biykem Bozkurt

|Sep 12, 2025
A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.

James Kim, Paolo Raggi, Anne-Marie Carreau

Pageof 4

Frequent Collaborators

4 joint publications

Rebecca Ag Christensen

4 joint publications

Carel W le Roux

4 joint publications

Domenica Rubino

3 joint publications

Elke Platz